Abstract
Influenza viruses are RNA viruses that are a major determinant of morbidity and mortality caused by respiratory disease. Influenza is highly contagious and has caused epidemics and pandemics for centuries. Most influenza infections are selflimited, but lower respiratory tract and cardiac complications can result in increases in hospitalizations and deaths. The recommended composition of influenza vaccine is updated annually in order to provide a vaccine that is antigenically well matched with the new influenza virus strains that are expected to cause epidemics. Influenza vaccination significantly reduces mortality; however, approximately one third of elderly Americans are not immunized annually. The nation’s goal is to increase the influenza vaccination rate among the elderly to 90%. Vaccination is the most effective measure for reducing the impact of influenza and is a cost-effective preventive health intervention for the elderly and individuals with chronic obstructive pulmonary disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Centers for Disease Control and Prevention: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2004, 53:1–44.
Thompson WW, Shay DK, Weintraub E, et al.: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179–186.
US Department of Health and Human Services: Healthy People 2010: Understanding and Improving Health, edn 2. Washington DC: US Government Printing Office; 2000.
Edwards KM, Dupont WD, Westrich MK, et al.: A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994, 169:68–76.
Govaert TM, Thijis CT, Masurel N, et al.: The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994, 272:1661–1665.
Vu T, Farish S, Jenkins M, Kelly H: A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002, 20:1831–1836. This is a detailed meta-analysis of effectiveness of influenza vaccine in persons aged older than 65 years and living in the community.
Gross PA, Hermogenes AW, Sacks HS, et al.: The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995, 123:518–527.
Hak E, Nordin J, Wei F, et al.: Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002, 35:370–377.
Wang CS, Wang ST, Lai CT, et al.: Reducing major causespecific hospitalization rates and shortening hospital stays after influenza vaccination. Clin Infect Dis 2004, 39:1604–1610.
Collins SD: Excess mortality from causes other than influenza and pneumonia during influenza epidemics. Public Health Report (Wash) 1932, 47:2159–2179.
Madjid M, Naghavi M, Litovsky S, Casscells SW: Influenza and cardiovascular disease. Circulation 2003, 108:2730–2736.
Naghavi M, Barlas Z, Siadaty S, et al.: Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000, 102:3039–3045.
Siscovick DS, Raghunathan TE, Lin D, et al.: Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000, 152:674–677.
Lavallee P, Perchaud V, Gautier-Bertrand M, et al.: Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002, 33:513–518.
Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B: Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. One-year follow-up. Eur Heart J 2004, 25:25–31.
Nichol KL, Nordin J, Mullooly J, et al.: Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003, 348:1322–1332. This is a well-conducted study that supports the theory that influenza vaccination protects against cardiac disease.
Nichol KL, Baken L, Nelson A: Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999, 130:397–403.
Wongsurakiat P, Maranetra KN, Wasi C, et al.: Acute respiratory illness in patients with COPD and effectiveness of influenza vaccination. A randomized controlled study. Chest 2004, 125:2011–2020. This is an excellent study that demonstrates the protective effects of inactivated influenza vaccine in patients with COPD.
Nguyen-Van-Tam JS, Nicholson KG: Influenza immunization; vaccine offer, request and uptake in high-risk patients during the 1991/2 season. Epidemiol Infect 1993, 111:347–355.
Rothbarth PH, Kempen BM, Sprenger MJ: Sense and nonsense of influenza vaccination in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 151:1682–1686.
Tata LJ, West J, Harrison T, et al.: Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax 2003, 58:835–839.
Betts RF, Treanor JJ: Approaches to improved influenza vaccination. Vaccine 2000, 18:1690–1695.
Treanor JJ, Mattison HR, Dumyati G, et al.: Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992, 117:625–633.
Gorse GJ, O’Connor TZ, Young SL, et al.: Efficacy of live, cold adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 2003, 21:2133–2144.
Postma MJ, Baltussen RM, Heijnen MA, et al.: Pharmacoeconomics of influenza in the elderly. Reviewing the available evidence. Drugs Aging 2000, 17:217–227.
Nichol KL, Goodman M: Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years. Vaccine 2002, 20:S21-S24. This is a comprehensive economic analysis of the cost effectiveness of influenza vaccination for the healthy elderly aged between 65 and 74 years.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lupatkin, H. Influenza vaccine in the elderly and chronic obstructive pulmonary disease. Curr Infect Dis Rep 7, 200–203 (2005). https://doi.org/10.1007/s11908-005-0035-8
Issue Date:
DOI: https://doi.org/10.1007/s11908-005-0035-8